Ultragenyx Reduces Workforce and Closes Two Rare Disease Programs

Previously missed November 3 restructuring: Ultragenyx announced an approximately 20% workforce reduction, GTX-102 Angelman-study wind-down and termination of UX701 for Wilson disease after study goals were not met. A contemporaneous 8-K estimates about $25…












